High-Risk Multiple Myeloma: Different Definitions, Different Outcomes?

Varování

Publikace nespadá pod Pedagogickou fakultu, ale pod Lékařskou fakultu. Oficiální stránka publikace je na webu muni.cz.
Autoři

PASZEKOVÁ Helena KRYUKOV Fedor KUBICZKOVÁ Lenka HÁJEK Roman ŠEVČÍKOVÁ Sabina

Rok publikování 2014
Druh Článek v odborném periodiku
Časopis / Zdroj Clinical lymphoma, myeloma & leukemia
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
Doi http://dx.doi.org/10.1016/j.clml.2013.09.004
Obor Onkologie a hematologie
Klíčová slova Cytogenetics; GEP; High-risk disease; MGUS; Multiple myeloma; Prognosis
Popis Multiple myeloma (MM) is a clonal plasma cell malignancy. Although MM is still not completely curable, it can be maintained at the level of a long-term chronic condition. Irrespective of the treatment strategy, relapse is still a major problem for most patients. Approximately 10% to 15% of all MM patients relapse early and have poor prognosis and outcome. Currently, there are many ways of identifying these high-risk patients using cytogenetics or molecular biology. Despite these various approaches to definition of high risk patients, a clear definition of high-risk MM has not been widely accepted. In this review, we discuss and compare various approaches, and their strengths and weaknesses in early identification of high-risk MM patients.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.